RIGHT TO TRY ACT House SponsorsRep. Mary E. Flowers 1/10/2017HouseSession Sine Die New Act225 ILCS 60/22from Ch. 111, par. 4400-22 Creates the Right to Try Act. Provides that an eligible patient with a terminal illness who has considered all other treatment options approved by the United States Food and Drug Administration may acquire from a manufacturer an investigational drug, biological product, or device that has successfully completed Phase 1 of a clinical trial, but has not been approved for general use by the United States Food and Drug Administration. Provides that a manufacturer may, but is not required to, provide an investigational drug, biological product, or device to an eligible patient, either with or without receiving compensation. Provides that an accident and health insurer may, but is not required to, provide coverage for an eligible patient seeking such a drug, product, or device. Provides that an entity responsible for Medicare certification may not take action against a health care provider's Medicare certification based solely on the health care provider's recommendation that a patient have access to an investigational drug, biological product, or device. Defines required terms. Amends the Medical Practice Act of 1987. Provides that the Department of Financial and Professional Regulation may not revoke, suspend, place on probation, reprimand, refuse to issue or renew, or take any other disciplinary or non-disciplinary action against the license or permit of a physician to practice medicine based solely on the physician's recommendation to an eligible patient regarding, or prescription for, or treatment with an investigational drug, biological product, or device. 1/15/2015HouseFiled with the Clerk by Rep. Mary E. Flowers 1/15/2015HouseFirst Reading 1/15/2015HouseReferred to Rules Committee 2/3/2015HouseAssigned to Judiciary - Civil Committee 3/19/2015HouseTo General Law Subcommittee 3/27/2015HouseRule 19(a) / Re-referred to Rules Committee 1/10/2017HouseSession Sine Die